Global Encephalitis Vaccine Market Size By Strain (Nakayama, Beijing, P-3, SA 14-14-2), By End User (Child, Adult), By Geographic Scope And Forecast

Encephalitis Vaccine Market Size And Forecast

Encephalitis Vaccine Market size was valued at USD 1269.13 Million in 2024 and is projected to reach USD 1875.65 Million by 2032, growing at a CAGR of 5.52% from 2026-2032.

The high mortality and morbidity rate caused due to the incidence of encephalitis virus is an alarming factor that is creating awareness among multiple regions and is driving the market growth. The inititives by various government and easy policies and proper treatment aids are contributing to the growth of the market. The Global Encephalitis Vaccine Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Encephalitis Vaccine Market Definition

Encephalitis virus is a mosquito-borne Flavivirus that can be transmitted from mosquitoes to wading birds, pigs and other vertebrate hosts. This virus can be prevented using Encephalitis vaccines. The incidence rate for the Encephalitis virus is in a general low but can depend on the location and the season. This virus can be prevented using Encephalitis vaccines. As an Encephalitis infected mosquito bite can also be transmitted through humans and most commonly occurs in rural agricultural areas, thus Asia Pacific has witnessed the most number of cases.

Global Encephalitis Vaccine Market Overview

The global market is witnessing expansion at a relatively higher growth rate owing to the high mortality rate caused due to the encephalitis virus. The rise in government initiatives and recommendations to immunize children is also aiding the growth of the market. Factors such as the growing number of campaigns and programs for the improvement in awareness regarding the benefits of these vaccines are acting as an opportunity for the market. These factors, collectively, are projected to increase the demand for Encephalitis Vaccine in the near future.

Global Encephalitis Vaccine Market Segmentation Analysis

The Global Encephalitis Vaccine Market is segmented on the basis of Strain, End-User, And Geography.

Encephalitis Vaccine Market, By Strain

• Nakayama
• Beijing
• P-3
• SA 14-14-2

Based on Strain, The market is bifurcated into Nakayama, Beijing, P-3, SA 14-14-2. The Nakayama segment accounts for the largest share in the encephalitis vaccine market by strain. It is followed by beijing.

Encephalitis Vaccine Market, By End-User

• Child
• Adult

Based on End-User, The market is bifurcated into Child and Adult. The Encephalitis is seen in children and the adult population. Comparitively, Adult section regisets more number of individuals that are affected each year.

Encephalitis Vaccine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Regional Analysis, The Global Encephalitis Vaccine Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America is anticipated to dominate the Encephalitis Vaccine Market and account for the largest share during the forecast period. Rise in investment from the government and public sector and programs to eradicate the disease from the region are the few factors expanding the growth of the market in the North American region. However, the Asia-Pacific market is anticipated to be the fastest-growing market during the forecast period. The prevalence of government-induced immunization programs, growing investment in R&D sector and entry of new vaccine manufacturers in the countries like India and China are majorly possible for the growth of the region.

Key Players

The "Global Encephalitis Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Liaoning Chengda, Valneva, Tiantan Biological Products, Sanofi Pasteur, Chengdu Institute of Biological Products, GlaxoSmithKline plc, Lanzhou Institute of Biological Products, Zhejiang Tianyuan Bio-Pharmaceutical, and Biken. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• Partnerships, Collaborations and Agreements
• April, 2020 Pfizer Inc. and Valneva SE ("Valneva") announced a collaboration to develop and commercialise Valneva's Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical trials.
• July 2021. GSK and Alector announce a global immuno-neurology collaboration for two clinical-stage first-in-class monoclonal antibodies for neurodegenerative diseases.
• June 23, 2020. Sanofi and Translate Bio are expanding their collaboration to develop mRNA vaccines for all infectious diseases.
• Mergers and Acquisitions
• September 2020 - Sanofi announced that its acquisition of Principia Biopharma Inc. ("Principia") for $100 per share in cash has been completed.
• April 2020. Over a year after the Rs31,700 crore mega-deal was first announced, Hindustan Unilever Ltd (HUL) has completed the merger of GlaxoSmithKline Consumer Healthcare Limited (GSKCH) with itself. HUL will distribute GSK brands such as Eno, Crocin, and Sensodyne in the country under the terms of the agreement.
• Product Launches and Product Expansions
• March 31, 2021. Sanofi will construct a new facility in Canada to increase the global availability of high-dose influenza vaccine.